Effects of antitumor agents on inducible prostacyclin production in vascular smooth muscle

European Journal of Pharmacology

Volumn 376, Issue 3, 1999, Pages 301-305

  Yasui, Kenichi ^a   Suehiro, Akira ^b   Kakishita, Eizo ^b   Wakabayashi, Ichiro ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cyclooxygenase 2; Daunorubicin; Prostacyclin; Smooth vascular muscle cell

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DAUNORUBICIN; FLUOROURACIL; INDOMETACIN; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; METHOTREXATE; PROSTACYCLIN; VINCRISTINE;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CYCLOOXYGENASE 2; DAUNORUBICIN; EPOPROSTENOL; INTERLEUKIN-1; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; MUSCLE, SMOOTH, VASCULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR;

EID: 0033064515     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00383-0     Document Type: Article

References (17)

1. Byrnes J.J., Baquerizo H., Gonzalez M., Hensely G.T. Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy. Am. J. Hematol. 21:1986;299-304.
2. Chabner, B.A., Allegra, C.J., Curt, G.A., Calabresi, P., 1996. Antineoplastic agents. In: Hardman, J.G., Limberd, L.E., Molinoff, P.B., Ruddon, R.W.R., Gilman, A.G. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, Health Professions Division, pp. 1233-1287.
3. Cwikiel M., Eskilsson J., Albertsson M., Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann. Oncol. 7:1996;731-737.
4. DeLoughery, T.G., Goodnight, Jr., S.H., 1996. Bleeding and thrombosis in hematologic neoplasia. In: Wiernik, P.H., Canellos, G.P., Dutcher, J.P., Kyle, R.A. (Eds.), Neoplastic Diseases of the Blood, 3rd edn. Churchill Livingstone, pp. 1177-1191.
5. Doll D.C., Yarbro J.W. Vascular toxicity associated with antineoplastic agents. Semin. Oncol. 19:1992;580-596.
6. Duperray A., Tranqui L., Alix J.-L., Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cell. Biochem. Pharmacol. 37:1988;4753-4757.
7. Lala P.K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int. J. Cancer. 73:1997;371-380.
8. Mitchell J.A., Larkin S., Williams T.J. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem. Pharmacol. 50:1995;1535-1542.
9. Moncada S. Biological importance of prostacyclin. Br. J. Pharmacol. 76:1982;3-31.
10. Ogawa K., Matsuzaki M., Miyashita H., Motomura S., Ito A., Okubo T. Pharmacokinetic study of daunorubicin in patients with leukemia. Chemotherapy. 35:1987;398-410.
11. Rimarachin J.A., Jacobson J.A., Szabo P., Maclouf J., Creminon C., Weksler B.B. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler. Thromb. 14:1994;1021-1031.
12. Ruschitzka F.T., Noll G., Luscher T.F. The endothelium in coronary artery disease. Cardiology. 88:1997;3-19.
13. Schirner M., Schneider M.R. Cicaprost inhibits metastases of animal tumors. Prostaglandins. 42:1991;451-461.
14. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125:1996;47-58.
15. Wakabayashi I., Hatake K., Kakishita E. Vasocontractile action of daunorubicin. J. Pharm. Pharmacol. 41:1989;801-802.
16. Wakabayashi I., Hatake K., Yoshimoto S., Sakamoto K. Inhibitory effects of daunorubicin on endothelium-dependent vasorelaxing response to acetylcholine of rat aorta. J. Pharm. Pharmacol. 46:1994;296-299.
17. Watson A.J. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol. Histopathol. 13:1998;591-597.